00:31 , May 15, 2019 |  BioCentury  |  Finance

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

Picking up one of Roche’s few remaining clinical cardiometabolism assets, Sofinnova Investments has joined Sofinnova Partners, 5AM Ventures and CinRx to launch CinCor with a $50 million series A and exclusive, worldwide rights to the...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
20:06 , Apr 24, 2019 |  BC Extra  |  Financial News

Why Satsuma investors see room for another migraine therapy

While a new class of drugs has captured most of the attention around migraine treatments, Satsuma's investors believe there's room in the marketplace for a new formulation of an old drug. Satsuma Pharmaceuticals Inc. (South...
23:07 , Mar 20, 2019 |  BioCentury  |  Finance

Flagship prepares for scale

With its newly closed $824 million Special Opportunities Fund II, Flagship Pioneering has deepened its pool of capital to invest in its portfolio companies as they seek to scale up with multiproduct platforms. Upon the...
02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
00:49 , Feb 16, 2019 |  BioCentury  |  Emerging Company Profile

NodThera: Inhibiting the inflammasome for NASH

NodThera Ltd. is tackling both the inflammation and fibrosis that drive NASH by inhibiting the NLRP3 inflammasome, a target few companies have interrogated for the indication. With a £28 million ($37 million) series A led...
22:50 , Feb 15, 2019 |  BioCentury  |  Finance

5AM seizes a new Opportunity

Alongside its newly closed sixth traditional venture fund, 5AM Ventures created its inaugural co-investment Opportunities I fund to give the firm more cash to participate in later venture rounds of its existing portfolio companies. According...
18:40 , Feb 15, 2019 |  BC Week In Review  |  Financial News

5AM raises nearly $500M for pair of funds

5AM Ventures said it closed its 5AM Opportunities I fund and 5AM Ventures VI fund, raising a total of $497 million. Opportunities I, 5AM's inaugural co-investment fund, raised $147 million to invest in the firm's...
18:21 , Feb 15, 2019 |  BC Week In Review  |  Financial News

Vor Biopharma raises $42M series A round

PureTech Health plc (LSE:PRTC) affiliate Vor Biopharma Inc. (Boston, Mass.) raised $42 million in a series A round led by 5AM Ventures and RA Capital to support development of the company's engineered hematopoietic stem cells...